Profile of veliparib and its potential in the treatment of solid tumors.

Abstract

Inhibition of poly(ADP-ribose) polymerase (PARP) is an attractive therapeutic strategy because of the importance of this pathway in restoring DNA damage. Small-molecule inhibitors of PARP appear most effective when used to treat tumors with underlying defects in DNA repair, or when combined with DNA-damaging agents. Veliparib is one of several recently developed oral inhibitors of PARP currently in clinical trials. This review summarizes the pharmacology, mechanisms of action, toxicity, and activity of veliparib seen in clinical trials to date. Also discussed are proposed mechanisms of resistance, potential biomarkers of activity, and issues regarding patient selection and combination therapies that may optimize use of this exciting new agent.

• Authors: Lars M Wagner
• Journal: OncoTargets and therapy (Onco Targets Ther) Vol. 8 Pg. 1931-9 ( 2015) ISSN: 1178-6930 [Print] New Zealand
• PMID: 26251615 (Publication Type: Journal Article, Review)